Department of Neurology, National Institute of Mental Health and NeuroSciences, Bangalore, India.
Epilepsia. 2011 Oct;52(10):1918-27. doi: 10.1111/j.1528-1167.2011.03189.x. Epub 2011 Jul 21.
Epilepsy following solitary cerebral cysticercosis (SCC) is possibly caused by perilesional gliosis, best visualized on magnetization transfer imaging (MTI).This study aims to describe development of gliosis around SCC by prospective serial MTI and to correlate this gliosis with long-term seizure outcome.
We randomized 123 patients with SCC and new-onset seizures to treatment with albendazole plus antiepileptics (treatment), or antiepileptics only (control), and performed magnetic resonance imaging (MRI) scans at 0, 3, 6, 12, and 24 months. Prospective follow-up data regarding seizure outcome up to 5 years later were collected. MRI studies were analyzed for lesion characteristics and perilesional magnetization transfer (MT) hyperintensity.
Clinical and radiologic data of 77 patients were analyzed. Demographic and seizure characteristics were similar in treatment and control groups. Clinical data were available up to 64 months after enrollment. At 12 months, 89.5% patients were seizure-free. MTI is more sensitive than routine imaging for detection of perilesional gliosis. Albendazole treatment did not affect imaging or clinical outcome, including development of gliosis. Independent of duration of follow-up, gliosis was associated with more seizures, and with seizure recurrence at 12 months; duration of seizures and antiepileptic therapy was longer. Gliosis was not dependent on seizure type or stage of degeneration at enrollment or persistence/calcification of the lesion.
Perilesional gliosis around SCC helps prognosticate seizure outcome. Poorer outcome in patients with persistent lesions is likely to be related to mechanisms other than gliosis. The lack of effect of albendazole on seizure outcome may be due to its inability to decrease formation of gliosis.
单纯性脑囊虫病(SCC)后癫痫可能是由病变周围神经胶质增生引起的,在磁化传递成像(MTI)上可得到最佳显示。本研究旨在通过前瞻性系列 MTI 描述 SCC 周围神经胶质增生的发展,并将其与长期癫痫发作结果相关联。
我们将 123 例 SCC 和新发癫痫患者随机分为阿苯达唑联合抗癫痫药物(治疗)或仅用抗癫痫药物(对照)治疗,并在 0、3、6、12 和 24 个月进行磁共振成像(MRI)扫描。收集 5 年后的前瞻性随访数据,以评估癫痫发作结果。对 MRI 研究进行分析,以评估病变特征和病变周围的磁化转移(MT)高信号。
对 77 例患者的临床和放射学数据进行了分析。治疗组和对照组的人口统计学和癫痫特征相似。临床数据可获得至登记后 64 个月。在 12 个月时,89.5%的患者无癫痫发作。MTI 比常规成像更敏感,可检测病变周围的神经胶质增生。阿苯达唑治疗并不影响影像学或临床结果,包括神经胶质增生的发展。独立于随访时间,神经胶质增生与更多的癫痫发作有关,与 12 个月时的癫痫复发有关;癫痫发作持续时间和抗癫痫治疗时间较长。神经胶质增生与发病时的癫痫发作类型或退变阶段、病变的持续性/钙化无关。
SCC 周围的病变周围神经胶质增生有助于预测癫痫发作结果。持续性病变患者的预后较差,可能与神经胶质增生以外的机制有关。阿苯达唑对癫痫发作结果无影响,可能是因为它不能减少神经胶质增生的形成。